ArticleNPJ precision oncology2026
Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.
Carlos Diego Holanda Lopes et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it